Substituting nevirapine for efavirenz: Risk factors for toxicity in nonnaive patients in a resource-constrained setting

AIDS

Volumn 23, Issue 17, 2009, Pages 2374-2376

  Van Griensven, Johan ^a   Un, Phally ^b   Phe, Thong ^b   Thai, Sopheak ^b   Lynen, Lutgarde ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Sihanouk Hospital Center of HOPE   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE;

CD4+ T LYMPHOCYTE; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; GENDER; GROUPS BY AGE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; NEVIRAPINE; RISK FACTORS; TREATMENT OUTCOME;

EID: 70449368759     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328331900c     Document Type: Letter

References (18)

1. Ruso G, Lichtner M, Traditi F, Vullo V. Is the time for an AIDS-free new generation different in resource-limited and industrialized countries? AIDS 2009; 23:293-296.
2. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485-1490.
3. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
4. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment and the risk of transmission of human immunodeficiency virus type1frommothertoinfant. PediatricAIDSClinicalTrialsGroup Protocol 076 Study Group. N Engl J Med 1996; 335:1621-1629.
5. O'SheaS, Newell ML, Dunn DT, Garcia-Rodriguez MC, Bates I, Rostron JM, et al. Maternal viral load, CD4 cell count and vertical transmission of HIV-1. J Med Virol 1998; 54:113-117.
6. Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS 1997; 11:437-444.
7. Weiser B, Nachman S, Tropper P, Viscosi KH, Grimson R, Baxter G, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci U S A 1994; 91:8037-8041.
8. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484-494.
9. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001; 15:621-627.
10. Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, et al. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997; 11:987-993.
11. Ateka GK, Lairson DR. School-based HIV/STD programs: do benefits justify costs? J Int Assoc Physicians AIDS Care (Chic Ill) 2008; 7:46-51.
12. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, et al. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS 2009; 23:1689-1699.
13. Thai S, Koole O, Un P, Ros S, De MP, Van DW, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009; 14:1-11.
14. Laureillard D, Prak N, Fernandez M, Ngeth C, Moeung S, Riel V, et al. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. HIV Med 2008; 9:514-518.
15. De Lazzari E, Leon A, Arnaiz JA, Martinez E, Knobel H, Negredo E, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008; 9:221-226.
16. Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis 2008; 46:933-940.
17. Cadogan M, Dalgleish AG. HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis 2008; 8:675-684.
18. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-361